TimesSquare Capital Management LLC lowered its position in Amedisys Inc (NASDAQ:AMED) by 2.8% during the first quarter, Holdings Channel reports. The fund owned 632,290 shares of the health services provider’s stock after selling 18,000 shares during the period. TimesSquare Capital Management LLC’s holdings in Amedisys were worth $32,304,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. purchased a new position in Amedisys during the first quarter worth about $123,000. State of Alaska Department of Revenue increased its position in Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares during the last quarter. Suntrust Banks Inc. increased its position in Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock worth $279,000 after buying an additional 107 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its position in Amedisys by 1.8% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock worth $325,000 after buying an additional 110 shares during the last quarter. Finally, Mason Street Advisors LLC increased its position in Amedisys by 7.1% in the first quarter. Mason Street Advisors LLC now owns 6,523 shares of the health services provider’s stock worth $333,000 after buying an additional 434 shares during the last quarter. Institutional investors and hedge funds own 97.92% of the company’s stock.

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Shares of Amedisys Inc (NASDAQ AMED) traded down 1.49% on Monday, reaching $62.79. The company had a trading volume of 231,334 shares. The stock has a 50-day moving average price of $58.36 and a 200-day moving average price of $49.60. Amedisys Inc has a 12 month low of $34.58 and a 12 month high of $64.32. The stock has a market cap of $2.12 billion, a PE ratio of 46.51 and a beta of 0.99.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, May 2nd. The health services provider reported $0.47 EPS for the quarter, beating the consensus estimate of $0.41 by $0.06. Amedisys had a return on equity of 12.60% and a net margin of 3.16%. The business had revenue of $370.46 million for the quarter, compared to the consensus estimate of $370.03 million. During the same quarter in the prior year, the business earned $0.33 earnings per share. Analysts predict that Amedisys Inc will post $2.07 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Amedisys Inc (AMED) Shares Sold by TimesSquare Capital Management LLC” was first posted by Financial Market News and is owned by of Financial Market News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.financial-market-news.com/2017/06/12/amedisys-inc-amed-shares-sold-by-timessquare-capital-management-llc.html.

A number of research analysts recently issued reports on the company. Royal Bank Of Canada reiterated a “hold” rating and set a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $59.00 price objective (up from $50.00) on shares of Amedisys in a report on Friday, March 3rd. Mizuho increased their price objective on Amedisys from $33.00 to $50.00 and gave the stock a “neutral” rating in a report on Wednesday, March 1st. Jefferies Group LLC increased their price objective on Amedisys from $50.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, March 1st. Finally, Zacks Investment Research downgraded Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $58.38.

In related news, insider Lawrence R. Pernosky sold 11,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 10th. The stock was sold at an average price of $58.97, for a total value of $678,155.00. Following the transaction, the insider now owns 30,093 shares in the company, valued at $1,774,584.21. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Scott G. Ginn sold 23,828 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $58.62, for a total value of $1,396,797.36. Following the completion of the transaction, the insider now owns 13,018 shares in the company, valued at approximately $763,115.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,828 shares of company stock worth $3,350,922. 2.80% of the stock is owned by company insiders.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.